OAW42Homo sapiens (Human)Cancer cell line

Also known as: OAW 42, OAW-42

🤖 AI SummaryBased on 15 publications

Quick Overview

Ovarian cancer cell line with known genetic characteristics.

Detailed Summary

OAW42 is a human ovarian cancer cell line derived from ascites, commonly used in cancer research. It exhibits specific genetic alterations and is part of a panel of cell lines used to study ovarian cancer biology. The cell line has been characterized for its response to various treatments and is utilized in studies related to tumor genetics and therapeutic strategies. Its utility in research is supported by its availability in multiple studies and its documented features in genomic and molecular analyses.

Research Applications

Genomic profilingDrug sensitivity testingTumor biology studies

Key Characteristics

Used in studies of ovarian cancer geneticsPart of the Cancer Cell Line Encyclopedia (CCLE)Characterized for mutations and gene expression
Generated on 6/17/2025

Basic Information

Database IDCVCL_1615
SpeciesHomo sapiens (Human)
Tissue SourceAscites[UBERON:UBERON_0007795]

Donor Information

Age46
Age CategoryAdult
SexFemale

Disease Information

DiseaseOvarian serous cystadenocarcinoma
LineageOvary/Fallopian Tube
SubtypeSerous Ovarian Cancer
OncoTree CodeSOC

DepMap Information

Source TypeECACC
Source IDACH-000704_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationNone reportedTP53---PubMed=19787792
MutationSimplePIK3CAp.His1047Leu (c.3140A>T)Unspecified-PubMed=32576280

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11
D10S1248
13
D12S391
18.3,21
D13S317
11
D16S539
12,13
D18S51
16,21
D19S433
13,14
D1S1656
11,12
D21S11
26
D22S1045
15,16
D2S1338
17
D2S441
12,14
D3S1358
15,16
D5S818
11,12
D7S820
8
D8S1179
13
FGA
22,25
Penta D
10
Penta E
12
TH01
6,7
TPOX
8,11
vWA
14,16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.

Velculescu V.E., Scharpf R.B.

Cell Rep. 25:2617-2633(2018).

Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.

Cell Rep. 18:2343-2358(2017).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Helleman J.

PLoS ONE 9:E103988-E103988(2014).

Evaluating cell lines as tumour models by comparison of genomic profiles.

Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.

Nat. Commun. 4:2126.1-2126.10(2013).

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Mills G.B., Hennessy B.T.

Mol. Oncol. 7:567-579(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

Wolf E., Gabius H.-J.

J. Cancer Res. Clin. Oncol. 127:375-386(2001).

Characterisation of seven human ovarian tumour cell lines.";

Wilson A.P., Dent M.F., Pejovic T., Hubbold L., Radford H.

Br. J. Cancer 74:722-727(1996).

Cytogenetics of a cell line derived from an ovarian papillary serous cystadenocarcinoma.

Hill S.M., Rodgers C.S., Hulten M.A., Wilson A.P.

Cancer Genet. Cytogenet. 12:321-327(1984).

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

Harrap K.R.

Br. J. Cancer 59:527-534(1989).

Web Resources